Ubac

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Lipoteichoic kisline iz Biofilma Oprijem del Streptococcus uberis, sev 5616

Available from:

Laboratorios Hipra, S.A.

ATC code:

QI02AB

INN (International Name):

Streptococcus uberis vaccine (inactivated)

Therapeutic group:

Govedo

Therapeutic area:

Imunologija za bovidae

Therapeutic indications:

Za aktivno imunizacijo zdravih krav in telic, da zmanjša pojavnost kliničnih intramammary okužb, ki jih povzroča Streptococcus uberis, da se zmanjša telesni število celic v Streptococcus uberis pozitivno četrtletju vzorcev mleka in zmanjšanje proizvodnje mleka izgube, ki jih povzroča Streptococcus uberis intramammary okužb.

Product summary:

Revision: 1

Authorization status:

Pooblaščeni

Authorization date:

2018-07-26

Patient Information leaflet

                                14
B. NAVODILO ZA UPORABO
15
NAVODILO ZA UPORABO
UBAC EMULZIJA ZA INJICIRANJE ZA GOVEDO
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za
sproščanje serij:
LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170- AMER (Girona)
SPAIN
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
UBAC emulzija za injiciranje za govedo
3.
NAVEDBA UČINKOVIN(E) IN DRUGE(IH) SESTAVIN
En odmerek (2 ml) vsebuje:
UČINKOVINA:
lipoteihojska kislina (LTA) iz komponente lepljivega biofilma (Biofilm
Adhesion Component - BAC)
bakterije
_Streptococcus uberis_
, sev 5616
...................................................................................
≥ 1 RPU*
*Enote relativne potence (ELISA)
DODATEK:
Montanid ISA
..............................................................................................................................907,1
mg
Monofosforil lipid A (MPLA)
Emulzija za injiciranje.
Bela homogena emulzija.
4.
INDIKACIJA(E)
Za aktivno imunizacijo zdravih krav in telic za zmanjšanje pojavnosti
kliničnih intramamarnih okužb,
ki jih povzroča
_Streptococcus uberis, _
in za zmanjšanje števila somatskih celic v vzorcih mleka z četrtin
vimen pozitivnih na
_Streptococcus uberis, _
in za zmanjšanje izgub pri proizvodnji mleka, ki so posledica
intramamarnih okužb, ki jih povzroča
_Streptococcus uberis. _
Nastop imunosti: približno 36 dni po drugem odmerku.
Trajanje imunosti: približno prvih 5 mesecev laktacije.
5.
KONTRAINDIKACIJE
Jih ni.
16
6.
NEŽELENI UČINKI
Po dajanju cepiva je zelo pogosta reakcija lokalna oteklina s premerom
več kot 5 cm na mestu injiciranja.
Ta oteklina izgine ali se opazno zmanjša do 17. dne po cepljenju. Po
dajanju cepiva je zelo pogosta
reakcija lokalna oteklina s premerom več kot 5 cm na mestu
injiciranja. Ta oteklina izgine ali se opazno
zmanjša do 17. dne po cepljenju. Vendar je v nekaterih primerih
oteklina vztrajala tudi do 4 tedne
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-12-2021
Public Assessment Report Public Assessment Report Bulgarian 14-08-2018
Patient Information leaflet Patient Information leaflet Spanish 07-12-2021
Public Assessment Report Public Assessment Report Spanish 14-08-2018
Patient Information leaflet Patient Information leaflet Czech 07-12-2021
Public Assessment Report Public Assessment Report Czech 14-08-2018
Patient Information leaflet Patient Information leaflet Danish 07-12-2021
Public Assessment Report Public Assessment Report Danish 14-08-2018
Patient Information leaflet Patient Information leaflet German 07-12-2021
Public Assessment Report Public Assessment Report German 14-08-2018
Patient Information leaflet Patient Information leaflet Estonian 07-12-2021
Public Assessment Report Public Assessment Report Estonian 14-08-2018
Patient Information leaflet Patient Information leaflet Greek 07-12-2021
Public Assessment Report Public Assessment Report Greek 14-08-2018
Patient Information leaflet Patient Information leaflet English 07-12-2021
Public Assessment Report Public Assessment Report English 14-08-2018
Patient Information leaflet Patient Information leaflet French 07-12-2021
Public Assessment Report Public Assessment Report French 14-08-2018
Patient Information leaflet Patient Information leaflet Italian 07-12-2021
Public Assessment Report Public Assessment Report Italian 14-08-2018
Patient Information leaflet Patient Information leaflet Latvian 07-12-2021
Public Assessment Report Public Assessment Report Latvian 14-08-2018
Patient Information leaflet Patient Information leaflet Lithuanian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-12-2021
Public Assessment Report Public Assessment Report Lithuanian 14-08-2018
Patient Information leaflet Patient Information leaflet Hungarian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 07-12-2021
Public Assessment Report Public Assessment Report Hungarian 14-08-2018
Patient Information leaflet Patient Information leaflet Maltese 07-12-2021
Public Assessment Report Public Assessment Report Maltese 14-08-2018
Patient Information leaflet Patient Information leaflet Dutch 07-12-2021
Public Assessment Report Public Assessment Report Dutch 14-08-2018
Patient Information leaflet Patient Information leaflet Polish 07-12-2021
Public Assessment Report Public Assessment Report Polish 14-08-2018
Patient Information leaflet Patient Information leaflet Portuguese 07-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 07-12-2021
Public Assessment Report Public Assessment Report Portuguese 14-08-2018
Patient Information leaflet Patient Information leaflet Romanian 07-12-2021
Public Assessment Report Public Assessment Report Romanian 14-08-2018
Patient Information leaflet Patient Information leaflet Slovak 07-12-2021
Public Assessment Report Public Assessment Report Slovak 14-08-2018
Patient Information leaflet Patient Information leaflet Finnish 07-12-2021
Public Assessment Report Public Assessment Report Finnish 14-08-2018
Patient Information leaflet Patient Information leaflet Swedish 07-12-2021
Public Assessment Report Public Assessment Report Swedish 14-08-2018
Patient Information leaflet Patient Information leaflet Norwegian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 07-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 07-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 07-12-2021
Patient Information leaflet Patient Information leaflet Croatian 07-12-2021
Public Assessment Report Public Assessment Report Croatian 14-08-2018

View documents history